Mark D. Tyson, II, MD, MPH, discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC.
Mark D. Tyson, II, MD, MPH
Advertisement
Mark D. Tyson, II, MD, MPH, is a urologic oncologist at Mayo Clinic.
Articles by Mark D. Tyson, II, MD, MPH
Mark D. Tyson, II, MD, MPH, discusses how TARA-002 could fit into the treatment landscape of BCG-naive NMIBC.
Mark D. Tyson, II, MD, MPH, discusses efficacy data with TARA-002 in patients with BCG-naive high-grade non–muscle-invasive bladder cancer.
Mark D. Tyson, II, MD, MPH, discussed the clinical implications of data from the primary analysis of the PATAPSCO trial in NMIBC.
Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.
Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.
Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
3
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
4
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
5